PAX2 and ovarian serous cystadenocarcinoma: Additionally, Liu X et al. 25 found that Pax2 was down-regulated by at least 4-fold in 594 ovarian serous cystadenocarcinomas in comparison with eight normal ovaries according to The Cancer Genome Atlas (TCGA).